title: Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.
authors.forename: D
authors.initials: D
authors.lastname: Wendling
authors.forename: B
authors.initials: B
authors.lastname: Auge
authors.forename: D
authors.initials: D
authors.lastname: Bettinger
authors.forename: A
authors.initials: A
authors.lastname: Lohse
authors.forename: G
authors.initials: G
authors.lastname: Le Huede
authors.forename: S
authors.initials: S
authors.lastname: Bresson-Hadni
authors.forename: E
authors.initials: E
authors.lastname: Toussirot
authors.forename: J-P
authors.initials: JP
authors.lastname: Miguet
authors.forename: G
authors.initials: G
authors.lastname: Herbein
authors.forename: V
authors.initials: V
authors.lastname: Di Martino
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D000069285:Infliximab; D025242:Spondylarthropathies / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab